Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2013 02:30 ET | Source: ALK Abello

Six-month interim report (Q2) 2013

Copenhagen, 2013-08-14 08:30 CEST (GLOBE NEWSWIRE) -- ALK (OMX: ALK B) (unaudited) Performance for the period (Comparative figures for 2012 are shown in brackets / sales growth is...
August 06, 2013 04:32 ET | Source: ALK Abello

ALK (OMX: ALK.B) schedules release of six-month interim report (Q2) 2013 on Wednesday, 14 August 2013

Copenhagen, 2013-08-06 10:32 CEST (GLOBE NEWSWIRE) -- ALK will hold a conference call for analysts and investors that day at 2.00 p.m. (CET) at which Jens Bager, President and CEO, Flemming...
August 06, 2013 04:32 ET | Source: ALK Abello

ALK (OMX: ALK.B) vil offentliggøre delårsrapport for første halvår (Q2) 2013 onsdag den 14. august 2013

København, 2013-08-06 10:32 CEST (GLOBE NEWSWIRE) -- ALK afholder samme dag kl. 14.00 (CET) en telefonkonference for analytikere og investorer, hvor adm. direktør Jens Bager, finansdirektør...
July 11, 2013 02:58 ET | Source: ALK Abello

Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma

Copenhagen, 2013-07-11 08:58 CEST (GLOBE NEWSWIRE) -- Copenhagen, Denmark; ALK (OMX: ALK.B) announces positive outcome of the second of two pivotal Phase III trials of its new allergy...
July 11, 2013 02:58 ET | Source: ALK Abello

Positive resultater fra pivotalt fase III-studie med ny tabletvaccine mod astma forårsaget af husstøvmider

København, 2013-07-11 08:58 CEST (GLOBE NEWSWIRE) -- København, Danmark; ALK (OMX: ALK.B) offentliggør positive resultater fra det andet af to pivotale fase III-studier med den nye...
June 19, 2013 08:03 ET | Source: ALK Abello

ALK offentliggør positive resultater fra pivotalt fase III-studie med ny tabletvaccine mod husstøvmideallergi

København, 2013-06-19 14:03 CEST (GLOBE NEWSWIRE) -- ALK offentliggør positive resultater fra det første af to pivotale fase III-studier med den nye tabletvaccine mod luftvejslidelser...
June 19, 2013 08:03 ET | Source: ALK Abello

ALK announces positive outcome of pivotal Phase III trial with new allergy immunotherapy tablet against house dust mite allergy

Copenhagen, 2013-06-19 14:03 CEST (GLOBE NEWSWIRE) -- ALK announces positive outcome of the first of two pivotal Phase III trials with its new allergy immunotherapy tablet for the treatment...
May 31, 2013 05:42 ET | Source: ALK Abello

ALK to present at two upcoming 2013 Investor Conferences

Copenhagen, 2013-05-31 11:42 CEST (GLOBE NEWSWIRE) -- ALK today announced that the Company will present at the Jefferies 2013 Global Healthcare Conference in New York, NY and the Goldman...
May 08, 2013 08:32 ET | Source: ALK Abello

Registreringsansøgning for tabletvaccine mod ragweedallergi accepteret til behandling af FDA

København, 2013-05-08 14:32 CEST (GLOBE NEWSWIRE) -- ALKs partner i Nordamerika, Merck (MSD uden for USA og Canada) har i dag offentliggjort, at de amerikanske sundhedsmyndigheder (FDA) har...
May 08, 2013 08:32 ET | Source: ALK Abello

License application for ragweed allergy immunotherapy tablet accepted for review by FDA

Copenhagen, 2013-05-08 14:32 CEST (GLOBE NEWSWIRE) -- Today, ALK’s partner for North America, Merck (known as MSD outside the USA and Canada), announced that the U.S. Food and Drug...